This article is more than 5 years old. Information may no longer be current.

VIDEO: Regeneron official provides dupilumab update

ATLANTA — Bola Akinlade, MD, MBA, FACP, clinical program leader, Regeneron, provided an update on studies involving dupilumab for the management of some dermatologic conditions at the annual meeting of the American Academy of Allergy, Asthma & Immunology.

“Patients in the open-label extension study have been followed for a little over 3 years. We have not seen any new safety signals, from what we’ve seen in the control studies, and very importantly we’ve seen sustained efficacy … a reduction in pruritus and the quality of life.”